Highlight
This quality-improvement study assessed three different prophylactic oxytocin infusion rates following vaginal delivery, demonstrating that a higher-rate infusion (30 international units over 1 hour) significantly reduced median quantitative blood loss compared with intermediate and low infusion regimens. Additionally, the high-rate group required fewer second-line uterotonics, while rates of postpartum hemorrhage and transfusion were unchanged across groups.
Study Background
Postpartum hemorrhage (PPH) remains a leading cause of maternal morbidity and mortality globally. Oxytocin administration immediately after vaginal birth is a cornerstone for PPH prevention due to its uterotonic effect. However, optimal dosing strategies of prophylactic oxytocin infusion remain uncertain, with wide practice variation regarding the infusion rate and total dosage. Balancing effective uterine contraction to minimize blood loss while avoiding adverse effects such as hypotension or fluid overload is essential.
This study addresses this gap by systematically comparing three distinct rates of prophylactic oxytocin infusion after vaginal birth in a large academic tertiary care setting, aiming to identify an optimal regimen for reducing blood loss and subsequent interventions.
Study Design
The study utilized a block-randomized quality-improvement initiative design conducted between June and October 2025 at a tertiary care academic center. Eligible participants were women with vaginal births, randomized over consecutive 2-week blocks to one of three prophylactic oxytocin regimens:
- Low-rate infusion: 10 international units (IU) over 2 hours at 83 mL/h
- Intermediate-rate infusion: 30 IU over 2 hours at 250 mL/h
- High-rate infusion: 30 IU over 1 hour at 500 mL/h
The primary endpoint was median quantitative blood loss measured immediately postpartum. Secondary endpoints included the requirement for second-line uterotonic agents, incidence of postpartum hemorrhage as defined by standard criteria, and rates of blood transfusion. Statistical analysis employed quantile regression, Jonckheere-Terpstra trend testing for ordinal changes, and Pearson’s chi-square for categorical variables. Interactions with body mass index (BMI) and intrapartum oxytocin exposure were examined via multivariable regression.
Key Findings
The study included 1,094 vaginal births: 377 in the low-rate group, 349 in the intermediate-rate group, and 368 in the high-rate group.
Blood Loss: The high-rate oxytocin infusion group had the lowest median quantitative blood loss (365 mL; interquartile range [IQR] 244–631 mL), compared with the intermediate-rate group (430 mL; IQR 260–735 mL) and low-rate group (465 mL; IQR 285–725 mL). The median difference in blood loss between the high-rate and low-rate groups was -100 mL (95% confidence interval [CI], -157 to -43 mL), with a statistically significant monotonic trend (P=.005).
Second-Line Uterotonic Use: The high-rate group required fewer additional uterotonics (21.5%) than the low-rate group (29.4%), with a statistically significant difference (P=.047), indicating improved uterine tone and hemorrhage prophylaxis.
Postpartum Hemorrhage and Transfusion Rates: No statistically significant differences were observed in PPH incidence or the need for blood transfusions across the three groups.
Other Analyses: No significant interactions of BMI or intrapartum oxytocin exposure with oxytocin infusion rate on blood loss were observed, supporting the robustness of findings.
Expert Commentary
The findings reinforce that administering a higher-dose oxytocin infusion over a shorter duration immediately postpartum effectively reduces blood loss after vaginal birth. From a pharmacodynamic perspective, the rapid delivery of 30 IU oxytocin likely achieves more sustained uterine contractions early in the postpartum period, which is critical in preventing uterine atony and hemorrhage.
Although the study was a quality-improvement initiative rather than a classical randomized controlled trial, its block-randomized design and large sample size offer credible evidence for clinical practice refinement. It is noteworthy that despite reduced blood loss and second-line uterotonic use, rates of diagnosed PPH and transfusion were unchanged, possibly reflecting that the absolute risk of severe hemorrhage is influenced by multifactorial clinical factors beyond oxytocin administration alone.
Limitations include its single-center design and absence of blinding, which may influence outcome assessment. Future multicenter randomized trials could corroborate these findings across diverse populations and settings.
Conclusion
This study demonstrates that a higher-rate prophylactic oxytocin infusion (30 IU over 1 hour) after vaginal birth is associated with significantly reduced postpartum blood loss and decreased need for second-line uterotonics compared to intermediate and low-rate regimens. These results support reassessment of current postpartum oxytocin infusion protocols to optimize hemorrhage prevention while maintaining safety profiles.
Implementing a standardized, high-rate oxytocin infusion protocol could improve maternal outcomes by mitigating early postpartum bleeding. Further research is warranted to evaluate long-term clinical benefits, safety in broader populations, and cost-effectiveness.
Funding and ClinicalTrials.gov
This was a quality-improvement initiative conducted at an academic tertiary care center with no external funding reported. The study is not registered with ClinicalTrials.gov.
References
- Synthesized data based on Litman EA et al. A Quality-Improvement Study Evaluating Three Postpartum Prophylactic Oxytocin Rates and Blood Loss After Vaginal Birth. Obstet Gynecol. 2026 Jun 25; PMID: 42348727.
- World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage. Geneva: WHO; 2012.
- American College of Obstetricians and Gynecologists. Practice Bulletin No. 183: Postpartum Hemorrhage. Obstet Gynecol. 2017;
